Abstract 5666: Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-1539 ◽

2018 ◽

Vol 25 (2) ◽

pp. 487-495 ◽

Cited By ~ 4

Author(s):

Magnus T. Dillon ◽

Lorna Grove ◽

Kate L. Newbold ◽

Heather Shaw ◽

Nicholas F. Brown ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Open Label ◽

Phase Ib ◽

Open Label Phase

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

Investigational New Drugs ◽

10.1007/s10637-013-9933-z ◽

2013 ◽

Vol 31 (5) ◽

pp. 1207-1216 ◽

Cited By ~ 19

Author(s):

Jean-Pascal Machiels ◽

Marie-Christine Kaminsky ◽

Ulrich Keller ◽

Tim H. Brümmendorf ◽

Thomas Goddemeier ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Palliative Treatment ◽

Toll Like Receptor ◽

First Line ◽

Phase Ib ◽

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

Cancer ◽

10.1002/cncr.30256 ◽

2016 ◽

Vol 122 (24) ◽

pp. 3803-3811 ◽

Cited By ~ 19

Author(s):

Antonio Jimeno ◽

Jean-Pascal Machiels ◽

Lori Wirth ◽

Pol Specenier ◽

Tanguy Y. Seiwert ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Phase Ib ◽

First Line Treatment

920P Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1035 ◽

2020 ◽

Vol 31 ◽

pp. S664

Author(s):

J. Guigay ◽

K-W. Lee ◽

M.R. Patel ◽

A. Daste ◽

D.J. Wong ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase Ib ◽

Platinum Refractory

Phase IB Trial of Imo-2055 in Combination with 5-Fu, Cisplatin and Cetuximab in 1st-Line PTS with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Annals of Oncology ◽

10.1016/s0923-7534(20)33600-0 ◽

2012 ◽

Vol 23 ◽

pp. ix342

Author(s):

J.P. Machiels ◽

M.C. Kaminsky ◽

U. Keller ◽

T.H. Brümmendorf ◽

T. Goddemeier ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase Ib ◽

Faculty Opinions recommendation of Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14264023.15777137 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Clinical Activity ◽

Molecular Response ◽

Faculty Opinions recommendation of Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954085.793459863 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Proteasome Inhibitor ◽

Eastern Cooperative Oncology Group ◽

Oncology Group ◽

Locally Recurrent

Faculty Opinions recommendation of Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954885.793461177 ◽

2012 ◽

Author(s):

Sandra Nuyts

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Preclinical Data ◽

Faculty Opinions recommendation of Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734912521.793555705 ◽

2019 ◽

Author(s):

Ricardo Hitt

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Second Line ◽

MO3-2 Prognostic significance of metastatic sites in recurrent or metastatic squamous cell carcinoma of the head and neck

Annals of Oncology ◽

10.1016/j.annonc.2021.05.565 ◽

2021 ◽

Vol 32 ◽

pp. S296

Author(s):

Ari Nishimura ◽

Tomoya Yokota ◽

Yoshiyuki Iida ◽

Tomoyuki Kamijo ◽

Takashi Mukaigawa ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Prognostic Significance ◽

Metastatic Sites